ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SNCE Science 37 Holdings Inc

5.75
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Science 37 Holdings Inc NASDAQ:SNCE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.75 5.72 5.74 0 01:00:00

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

27/06/2024 2:41pm

GlobeNewswire Inc.


Science 37 (NASDAQ:SNCE)
Historical Stock Chart


From Jun 2024 to Jul 2024

Click Here for more Science 37 Charts.

Science 37, a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 efficiently identified, recruited, medically qualified, and enrolled patients without geographic restrictions.

"Enrollment delays can be costly and create immense pressure to deliver results,” commented Brian Smith, Senior VP of Project Delivery at Science 37. “Traditionally, study teams address this by starting up more sites and/or adding patient recruitment. However, today's study teams need solutions that expand patient access to their study regardless of their location. Science 37 provides access to patient populations that no traditional site can match."

Science 37 has successfully supplemented enrollment in a variety of studies, including Phase 2 through Phase 4 and Observational trials across therapeutic areas such as Hematology, Hepatology, Infectious Diseases, CNS, Oncology, and Rare Diseases like Primary Sclerosing Cholangitis and Fragile X Syndrome.

Science 37’s Patient Recruitment is available on a standalone basis to clinical research sponsors and CROs looking to enhance their patient enrollment efforts, or in combination with Science 37’s industry-leading flagship Virtual Site, the Metasite™, as part of an accelerated patient access offering. For more information, please visit www.science37.com.

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37PR@science37.com

1 Year Science 37 Chart

1 Year Science 37 Chart

1 Month Science 37 Chart

1 Month Science 37 Chart

Your Recent History

Delayed Upgrade Clock